Abstract
AbstractReference materials are critical in assay development for calibrating and assessing their suitability. The devasting nature of the COVID-19 pandemic and subsequent proliferation of vaccine platforms and technologies has meant that there is even a greater need for standards for immunoassay development, which are critical to assess and compare vaccines’ responses. Equally important are the standards needed to control the vaccine manufacturing processes. Standardized vaccine characterization assays throughout process development are essential for a successful Chemistry, Manufacturing and Controls (CMC) strategy. In this perspective paper, we advocate for reference material incorporation into assays and their calibration to International Standards from preclinical vaccine development through control testing and provide insight into why this is necessary. We also provide information on the availability of WHO international antibody standards for CEPI-priority pathogens.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Infectious Diseases,Pharmacology,Immunology
Reference27 articles.
1. ISO. International Standardization Organization https://www.iso.org/home.html (2023).
2. Bioanalytical Method Validation and Study Sample Analysis M10 (ICH Harmonised Guideline, 2022).
3. Expert Committee on Biological Standardization [website]. World Health Organization. https://www.who.int/groups/expert-committee-on-biological-standardization.
4. Krause P, F. T. et al. COVID-19 vaccine trials should seek worthwhile efficacy. Lancet 12, 741–743 (2020). 396(10253).
5. Liu, M. A., Zhou, T., Sheets, R. L., Meyer, H. & Knezevic, I. WHO informal consultation on regulatory considerations for evaluation of the quality, safety and efficacy of RNA-based prophylactic vaccines for infectious diseases, 20–22 April 2021. Emerg. Microbes Infect. 11, 384–391 (2022).
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献